Navigation Links
Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron

-- Infections (which sometimes cause death)

-- Lung problems (like trouble breathing, pneumonia)

-- Eye problems (like blurred vision, loss of vision)

-- Autoimmune problems (such as psoriasis, thyroid problems)

-- Heart problems (including chest pain and, rarely, a heart attack)

-- Liver problems (rarely, liver function worsens). Patients with both the hepatitis C virus and HIV can have an increased chance of having liver failure during PEGASYS treatment. Change in a blood test that measures liver inflammation occurs more often in patients with hepatitis B. If you have a rise in this blood test you may need to be watched more closely with additional blood tests.

Tell your doctor immediately if you think you or your partner may be pregnant or if any of these symptoms occur.

About DDW

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the Washington Convention Center, Washington, DC. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit www.ddw.org.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years, the Roche Group has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health an
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
3. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
9. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
10. Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
11. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
Post Your Comments:
(Date:10/8/2008)...NDRIA, Va., Oct. 8 /PRNewswire-USNewswire/ -- The ...ople die from HIV/AIDS in,sub-Saharan Africa. More...aharan Africa have already died of AIDS. The Found...g to ensure the dying and their families,find comp...e. FHSSA,s,innovative partnering initiative links ...
(Date:10/8/2008)...anolimumab Program to be Discontinued and Headcoun...ults of its Portfolio Review; Zanolimumab Program...e Number of Employee...- Genmab A/S (OMX: GEN),announced today that it is...D4(R)). In addition, as a result of a portfolio re...
(Date:10/8/2008)... France, Oct. 8 /- Vical Incorporated...nical data and new nonclinical data,demonstrating ...oadly,applicable in DNA- and protein-based infecti...ines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,S...present the data today,Wednesday, October 8, at t...
(Date:10/7/2008)...luates the efficacy of new device for detecting po...ng colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswire...nnual Scientific Meeting in Orlando (ACG 2008), re...nted results from a,multi-institutional clinical s...R) Retroscope(R), a new device that is designed to...
Breaking Medicine Technology:In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Doctors Often Fail to Spot Suicidal Patients 1926 1Doctors Often Fail to Spot Suicidal Patients 1926 2Doctors Often Fail to Spot Suicidal Patients 1926 3Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 1Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 2USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 1USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 2SalesForce4Hire Opens New Office 1920 1SalesForce4Hire Opens New Office 1920 2
...wire-FirstCall/ -- Shire plc ,the market leader i...isorder (ADHD), announced that it will present key...t the American Psychiatric,Association (APA) annua..."The upcoming clinical research to be presented at... the science of ADHD treatment,",said Eliseo Salin...
...5, 2007 - Gemin X Biotechnologies,Inc. announced t...demonstrated that its lead compound, obatoclax (GX...l Lymphoma (MCL) cell lines and,primary cells from...molecule specifically designed to inhibit all rele...ted cancer target, thus restoring,the natural cell...
Other Medicine Technology:Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 2Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 3Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 4Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 5Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 6Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 7Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...1 or juvenile-onset diabetes also works in a rat m...g to a new report from researchers at Washington U...g that we can cure type 2 diabetes in the same way... type 2 diabetes is almost 20 times more prevalent...
...es the establishment of the Center for Celiac Dise...ose//, treat and provide support for patients and ...ac disease is unable to digest gluten, a common in...g bread, pasta and even condiments,” said Ritu Ver...
...hydrate molecules so as to prepare for an invasion...of Florida, which has been published in the curren...not only humans but viruses too that crave for car...ed that the viruses hang on to the carbohydrates t...
...f Adults Cannot Manage Without Cell Phones.The res...shire in Stoke-on-Trent, who had conducted the res...ictive behavior when it comes to their cell phones...mobile phones, he observed that some of the behavi...
Other Medicine News:Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 2Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 3Health News:Center for Celiac Disease Opens 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 3
The Affinity pacemaker family offers some of today's smallest, truly automatic devices. Featuring the most effective combination of advanced technologies ever seen, the Affinity DR pacemaker incorpor
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks.
The first-ever completely automatic pacemaker, EnPulse offers exclusive features that make it sophisticated yet simple to use. It performs a wide range of diagnostic tests on a regular basis, without
...ystem 3000Dx (GCS3000Dx) is the first microarray i...oratories. The system consists of the FS450Dx Flui...g and staining of the array, the GCS3000Dx Scanner...croarrays to be scanned without operator intervent...
Medicine Products: